Health Care [ 3/12 ] | Pharmaceuticals [ 37/74 ]
NASDAQ | Common Stock
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors.
In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial.
The company was incorporated in 1998 and is headquartered in Menlo Park, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 30, 24 | 0.41 Increased by +46.43% | 0.28 Increased by +46.43% |
| Jul 29, 24 | 0.32 Increased by +28.00% | 0.23 Increased by +39.13% |
| May 1, 24 | 0.25 Increased by +78.57% | 0.22 Increased by +13.64% |
| Feb 15, 24 | 0.28 Increased by +100.00% | 0.26 Increased by +7.69% |
| Nov 1, 23 | 0.28 Decreased by -6.67% | 0.22 Increased by +27.27% |
| Aug 2, 23 | 0.25 Increased by +4.17% | 0.15 Increased by +66.67% |
| May 3, 23 | 0.14 Decreased by -30.00% | 0.19 Decreased by -26.32% |
| Feb 28, 23 | 0.14 Decreased by -46.15% | 0.23 Decreased by -39.13% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 182.55 M Increased by +47.69% | 46.69 M Increased by +48.80% | Increased by +25.58% Increased by +0.75% |
| Jun 30, 24 | 163.80 M Increased by +39.15% | 35.49 M Increased by +28.92% | Increased by +21.67% Decreased by -7.35% |
| Mar 31, 24 | 146.81 M Increased by +38.95% | 27.76 M Increased by +74.83% | Increased by +18.91% Increased by +25.82% |
| Dec 31, 23 | 135.41 M Increased by +31.39% | 31.36 M Increased by +88.87% | Increased by +23.16% Increased by +43.75% |
| Sep 30, 23 | 123.60 M Increased by +21.50% | 31.38 M Decreased by -9.33% | Increased by +25.39% Decreased by -25.38% |
| Jun 30, 23 | 117.72 M Increased by +13.86% | 27.53 M Increased by +0.42% | Increased by +23.39% Decreased by -11.80% |
| Mar 31, 23 | 105.65 M Increased by +12.77% | 15.88 M Decreased by -30.35% | Increased by +15.03% Decreased by -38.23% |
| Dec 31, 22 | 103.06 M Increased by +4.28% | 16.60 M Decreased by -48.21% | Increased by +16.11% Decreased by -50.34% |